Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application
Synopsis
The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.
Lantheus Holdings, Inc. said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.
The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29. The extended deadline is expected to give the agency additional time to review and consider further manufacturing related information submitted by Lantheus, it said.
The extension, however, is not related to the efficacy or safety data of LNTH-2501, a radioactive diagnostic kit for detecting somatostatin receptor positive neuroendocrine tumors in adults as well as pediatric patients, the company added.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.